VAŠKŮ, Anna, Julie BIENERTOVÁ VAŠKŮ, Nečas MIROSLAV and Vladimír VAŠKŮ. Matrix Metalloproteinase-2 Promoter Genotype as a Marker of Cutaneous T-Cell Lymphoma Early Stage. Journal of Biomedicine and Biotechnology. USA, New York: Hindawi Publishing Corporation, 2010, vol. 2010, 2010:80590, p. 1-5. ISSN 1110-7243. |
Other formats:
BibTeX
LaTeX
RIS
@article{890561, author = {Vašků, Anna and Bienertová Vašků, Julie and Miroslav, Nečas and Vašků, Vladimír}, article_location = {USA, New York}, article_number = {2010:80590}, keywords = {cutaneous T-cell lymphoma; mycosis fungoides; matrix metalloproteinase 2; promoter; genotype}, language = {eng}, issn = {1110-7243}, journal = {Journal of Biomedicine and Biotechnology}, title = {Matrix Metalloproteinase-2 Promoter Genotype as a Marker of Cutaneous T-Cell Lymphoma Early Stage}, volume = {2010}, year = {2010} }
TY - JOUR ID - 890561 AU - Vašků, Anna - Bienertová Vašků, Julie - Miroslav, Nečas - Vašků, Vladimír PY - 2010 TI - Matrix Metalloproteinase-2 Promoter Genotype as a Marker of Cutaneous T-Cell Lymphoma Early Stage JF - Journal of Biomedicine and Biotechnology VL - 2010 IS - 2010:80590 SP - 1-5 EP - 1-5 PB - Hindawi Publishing Corporation SN - 11107243 KW - cutaneous T-cell lymphoma KW - mycosis fungoides KW - matrix metalloproteinase 2 KW - promoter KW - genotype N2 - The aim of the study was to investigate the DNA polymorphic genotype in MMP2 promoter gene as a potential candidate region for the development of the cutaneous T cell lymphoma (CTCL) andor its progression. A total of 89 Czech patients with CTCL (including 23 patients with large plaque parapsoriasis) were compared to 198 controls. The three selected polymorphisms in the promoter of MMP2 gene were determined using the PCR based methodology with RFLP. In our cohort, the associated GGCCTT MMP2 promoter genotype was highly significantly more frequent in CTCL Ia stage patients compared to patients with parapsoriasis, the tests having high sensitivity and specificity (78%, 83%, resp.). To conclude, use of associated MMP2 promoter genotype as a DNA marker might make it possible to distinguish between the patients with parapsoriasis and those with CTCL stage Ia, which could substantially improve possibilities of clinical diagnostics, therapy design, and prognosis of this serious condition in the early stages. ER -
VAŠKŮ, Anna, Julie BIENERTOVÁ VAŠKŮ, Nečas MIROSLAV and Vladimír VAŠKŮ. Matrix Metalloproteinase-2 Promoter Genotype as a Marker of Cutaneous T-Cell Lymphoma Early Stage. \textit{Journal of Biomedicine and Biotechnology}. USA, New York: Hindawi Publishing Corporation, 2010, vol.~2010, 2010:80590, p.~1-5. ISSN~1110-7243.
|